Teladoc Health Inc (TDOC): Street Finally Waking Up

Currently, there are 166.66M common shares owned by the public and among those 165.21M shares have been available to trade.

However, the script later moved the day high at 15.65, down -3.50%. The company’s stock has a 5-day price change of -4.97% and -33.50% over the past three months. TDOC shares are trading -33.50% year to date (YTD), with the 12-month market performance down to -41.34% lower. It has a 12-month low price of $14.29 and touched a high of $30.41 over the same period. TDOC has an average intraday trading volume of 4.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.01%, -17.56%, and -29.25% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Teladoc Health Inc (NYSE: TDOC) shares accounts for 77.39% of the company’s 166.66M shares outstanding.

It has a market capitalization of $2.39B and a beta (3y monthly) value of 0.94. The earnings-per-share (ttm) stands at -$1.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.72% over the week and 3.12% over the month.

Earnings per share for the fiscal year are expected to increase by 22.34%, and 31.18% over the next financial year.

Looking at the support for the TDOC, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on February 29, 2024, with the firm’s price target at $22. Leerink Partners coverage for the Teladoc Health Inc (TDOC) stock in a research note released on February 26, 2024 offered a Market Perform rating with a price target of $17. DA Davidson was of a view on January 17, 2024 that the stock is Neutral, while Barclays gave the stock Overweight rating on January 03, 2024, issuing a price target of $26. Stephens on their part issued Equal-Weight rating on April 12, 2023.

Most Popular

Related Posts